This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
Characterising Kynurenine 3-Monooxygenase (KMO) As A Therapeutic Target For Huntington’s Disease
Investments > €500k
United Kingdom
Huntington’s disease
2016